See more : Longzhou Group Co., Ltd. (002682.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of RIV Capital Inc. (CNPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RIV Capital Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dominion Minerals Limited (DLM.AX) Income Statement Analysis – Financial Results
- Kismet Acquisition One Corp (KSMT) Income Statement Analysis – Financial Results
- Inventure Growth & Securities Limited (INVENTURE.NS) Income Statement Analysis – Financial Results
- Cinderson Tech (Suzhou) Co Ltd Ordinary Shares – Class A (603344.SS) Income Statement Analysis – Financial Results
- Allied Telesis Holdings K.K. (ATSKF) Income Statement Analysis – Financial Results
RIV Capital Inc. (CNPOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rivcapital.com
About RIV Capital Inc.
RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 5.64M | 6.81M | 1.43M | 10.10M | 8.13M | 3.16M | 70.64M |
Cost of Revenue | 6.36M | 4.37M | 0.00 | 53.63M | -4.06M | -1.70M | 0.00 |
Gross Profit | -721.51K | 2.44M | 1.43M | -43.53M | 12.18M | 4.87M | 70.64M |
Gross Profit Ratio | -12.80% | 35.77% | 100.00% | -431.09% | 149.90% | 153.77% | 100.00% |
Research & Development | -10.73 | 0.00 | -21.19 | -8.52 | -2.83 | 2.15 | 0.00 |
General & Administrative | 0.00 | 17.97M | 7.76M | 6.09M | 13.02M | 22.32M | 2.41M |
Selling & Marketing | 0.00 | 351.00K | 0.00 | 0.00 | 0.00 | 560.89K | 7.86M |
SG&A | -8.66 | 20.50M | 7.76M | 6.09M | 13.02M | 22.32M | 10.28M |
Other Expenses | -63.77M | 1.22M | 561.96K | -1.13M | 969.69K | 236.62K | 1.29 |
Operating Expenses | 15.89M | 20.83M | 10.44M | 81.04M | 13.33M | 22.28M | 10.28M |
Cost & Expenses | 22.25M | 25.20M | 10.44M | 81.04M | 13.33M | 22.28M | -10.28M |
Interest Income | 0.00 | 653.00K | 1.51M | 12.75M | 4.86M | 1.63M | 0.00 |
Interest Expense | 11.09M | 17.22M | 5.78M | 22.17K | 25.37K | 0.00 | 81.60K |
Depreciation & Amortization | 22.25M | 2.00M | 58.01M | 37.79M | 36.81M | -5.32M | 43.82K |
EBITDA | -15.27M | -16.04M | -9.56M | -101.94M | -8.45M | -20.50M | -163.21K |
EBITDA Ratio | -270.84% | -235.70% | -670.26% | -1,009.54% | -103.95% | -647.80% | -0.23% |
Operating Income | 1.34M | -22.85M | -48.80M | -119.12M | -29.57M | 6.01M | 60.36M |
Operating Income Ratio | 23.77% | -335.63% | -3,421.16% | -1,179.66% | -363.77% | 189.94% | 85.45% |
Total Other Income/Expenses | 102.29M | -147.21M | -37.40M | -49.67M | -23.40M | 25.36M | -81.60K |
Income Before Tax | -15.27M | -182.18M | -52.20M | -120.63M | -28.62M | 6.25M | -43.82K |
Income Before Tax Ratio | -270.84% | -2,676.29% | -3,659.04% | -1,194.65% | -352.15% | 197.42% | -0.06% |
Income Tax Expense | -16.61M | -2.92M | -9.98M | -14.63M | -35.94K | 3.31M | -43.82K |
Net Income | -80.38M | -179.26M | -42.21M | -106.01M | -28.59M | 2.93M | -43.82K |
Net Income Ratio | -1,425.74% | -2,633.45% | -2,959.09% | -1,049.79% | -351.71% | 92.71% | -0.06% |
EPS | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
EPS Diluted | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
Weighted Avg Shares Out | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
Weighted Avg Shares Out (Dil) | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
RIV Capital Reports Financial Results for the Third Quarter Ended September 30, 2024
RIV Capital Provides Update on Revenue Performance and Synergy Realization Ahead of Anticipated Business Combination
RIV Capital Establishes Distribution Partnership with Nabis
RIV Capital and Cansortium Receive New York State Cannabis Control Board Approval for Change of Control
RIV Capital and Etain Commence Adult-Use Sales at Kingston Dispensary
RIV Capital and Cansortium Celebrate the Successful Launch of MOODS in New York
RIV Capital Appoints David E Vautrin to Interim CEO
RIV Capital and Etain Open Second Adult-Use Location in New York
RIV Capital's revenue more than doubles as New York cannabis market gears up
RIV Capital Reports Financial Results for the Second Quarter Ended June 30, 2024
Source: https://incomestatements.info
Category: Stock Reports